AXSM Historical PE Ratio Notes

— Axsome Therapeutics (AXSM) is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders, such as depression, migraines, and Alzheimer’s disease agitation. The company's lead products, including Auvelity and Sunosi, target large, underserved patient populations, offering the potential for significant growth if these drugs gain further market traction. When reviewing historical PE (price-to-earnings) ratio data for AXSM, it’s important to note that early-stage biotechs often report little to no earnings, as substantial R&D expenses and limited initial revenues usually dominate their financials—sometimes resulting in extremely high or even negative PE ratios before product launches. As Axsome Therapeutics achieved commercial milestones, the market's expectations for future profitability shifted, which is often reflected in changing PE ratios. Fluctuations in historical PE are therefore closely tied to the company's drug development progress, FDA approvals, and commercial success. When charting AXSM's past PE ratios, be mindful that periods of low or negative earnings often skew this metric, making it less reliable until meaningful and consistent profits are established.

On this page we presented the AXSM Historical PE Ratio information for Axsome Therapeutics' stock. The average AXSM historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AXSM historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AXSM historical PE result, against the recent PE: when this page was posted on 5/8/2026, the most recent closing price for AXSM had been 217.38, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on AXSM or any other given stock, valuation analysis for AXSM can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Axsome Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AXSM. Thanks for visiting, and the next time you need to research AXSM Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.